# US 2024/0199676 A1 · Antiviral compounds and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199676 A1
- Document ID: US20240199676A1
- Status: Published application
- Kind: A1
- Application number: 18/174,474
- Filed: 2023-02-24
- Published: 2024-06-20
- Earliest claimed: 2022-03-03
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Byoung-Kwon Chun; Michael O. Clarke; Deeba Ensan; Richard L. Mackman; Devan Naduthambi; Dustin S. Siegel
- Web page: https://patentgrep.com/patent/US20240199676A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07H 7/06: Heterocyclic radicals
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is OH;
R2 is OH; or
R3 is C(O)R7;
R7 is C1-C8 alkyl, C3-C8 carbocyclyl, C6-C10 aryl, 4 to 6 membered heterocyclyl containing 1, 2, or 3 O, or 5 to 6 membered heteroaryl containing 1, 2, or 3 heteroatoms selected from N, O, and S;
wherein the alkyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl of R7 are each, independently, optionally substituted with one, two or three substituents independently selected from the group consisting of halo, oxo, cyano, —N3, —OR8, C1-C8alkyl, —NR9R10, C3-C8 carbocyclyl optionally substituted with C1-C6 alkyl, and phenyl optionally substituted with one, two, or three substituents independently selected from halo, cyano, and C1-C6 alkyl; and
each R8 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
each R9 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl;
each R10 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl; and
Base is
wherein
R11 is C1-C6 alkyl substituted with —OP(O)(OH)2 or —OC(O)R12;
R12 is C1-C8 alkyl; and
R13 is C1-C6 alkyl substituted with —OP(O)(OH)2 or —OC(O)R12.

### Claim at position 2

2-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein R3 is

### Claim at position 4

12-50. (canceled)

### Claim 51 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein R7 is C1-C8 alkyl.

### Claim 52 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein R7 is C1-C6 alkyl.

### Claim 53

(canceled)

### Claim 54 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein R7 is C3-C8 carbocyclyl.

### Claim at position 9

55-91. (canceled)

### Claim 92 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein Base is

### Claim at position 11

93-95. (canceled)

### Claim 96 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein Base is

### Claim at position 13

97-100. (canceled)

### Claim 101 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is

### Claim at position 15

102-121. (canceled)

### Claim 122 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim at position 17

123-126. (canceled)

### Claim 127 (depends on 122)

A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a therapeutically effective amount of a pharmaceutical composition of claim 122.

### Claim at position 19

128-137. (canceled)

### Claim 138 (depends on 127)

The method of claim 127, wherein the viral infection is a pneumoviridae virus infection.

### Claim 139 (depends on 138)

The method of claim 138, wherein the pneumoviridae virus infection is respiratory syncytial virus infection.

### Claim 140 (depends on 138)

The method of claim 138, wherein the pneumoviridae virus infection is human metapneumovirus infection.

### Claim 141 (depends on 127)

The method of claim 127, wherein the viral infection is a picornaviridae virus infection.

### Claim 142 (depends on 141)

The method of claim 141, wherein the picornaviridae virus infection is human rhinovirus infection.

### Claim at position 25

143-165. (canceled)

### Claim 166 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 167 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 168 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 169 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is

### Claim 170 (depends on 1)

The compound of claim 1, or the pharmaceutically acceptable salt thereof, wherein the compound is
